Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer.
Androgen Receptor Antagonists
/ pharmacology
Animals
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Benzamides
Cell Line, Tumor
/ transplantation
Disease Models, Animal
Disease Progression
Drug Resistance, Neoplasm
/ drug effects
Humans
Male
Mice
Nitriles
Phenylthiohydantoin
/ analogs & derivatives
Prostatic Neoplasms, Castration-Resistant
/ drug therapy
Receptors, Androgen
/ metabolism
Signal Transduction
/ drug effects
Taxoids
/ pharmacology
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
received:
26
11
2018
revised:
28
10
2019
accepted:
30
01
2020
pubmed:
8
2
2020
medline:
21
10
2020
entrez:
8
2
2020
Statut:
ppublish
Résumé
Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well as in patients previously exposed to chemotherapy. However, resistance to enzalutamide and enzalutamide withdrawal syndrome have been reported. Thus, reliable and integrated preclinical models are required to elucidate the mechanisms of resistance and to assess therapeutic settings that may delay or prevent the onset of resistance. In this study, the prostate cancer multistage murine model TRAMP and TRAMP-derived cells have been used to extensively characterize
Identifiants
pubmed: 32029552
pii: 0008-5472.CAN-18-3637
doi: 10.1158/0008-5472.CAN-18-3637
doi:
Substances chimiques
AR protein, mouse
0
Androgen Receptor Antagonists
0
Benzamides
0
Nitriles
0
Receptors, Androgen
0
Taxoids
0
Phenylthiohydantoin
2010-15-3
cabazitaxel
51F690397J
enzalutamide
93T0T9GKNU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1564-1577Informations de copyright
©2020 American Association for Cancer Research.